#USA #New York #Gross Law Firm #MLTX #MoonLake Immunotherapeutics

Class Action Lawsuit Against MoonLake Immunotherapeutics

The Gross Law Firm has issued a crucial notification for shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action lawsuit. This notice is particularly important for investors who acquired shares between March 10, 2024, and September 29, 2025. This communication outlines the opportunity for current shareholders to engage with the legal process, as they may have the chance to become the lead plaintiff in the case.

Details of the Class Period

During the specified class period, allegations have emerged that the company may have misled investors through materially false claims regarding its drug candidates, primarily SLK and BIMZELX. The complaint details that the company failed to disclose significant information about the drugs, including that both candidates target the same inflammatory cytokines (IL-17A and IL-17F). Furthermore, the lawsuit alleges that claims regarding SLK's advantages over BIMZELX lack a reasonable basis.

Allegations Summarized

1. Unsubstantiated Claims: It is asserted that SLK's unique Nanobody structure does not provide a clinical benefit compared to the more traditional monoclonal structure of BIMZELX.
2. Clinical Efficacy Doubts: There are doubts about the efficacy of SLK, particularly regarding its supposed superior tissue penetration not translating into better clinical outcomes.
3. Misleading Statements: Overall, the defendants allegedly released optimistic statements concerning SLK’s superiority that did not reflect the reality of its clinical efficacy and underlying science.

The lawsuit contends that these unfounded claims led to a misrepresentation of the company's stock value, artificially inflating it, which subsequently resulted in investor losses when the truth came to light.

Important Dates and Next Steps for Shareholders

Shareholders who purchased shares of MLTX during the class period are encouraged to reach out to the Gross Law Firm for potential involvement in this case. The deadline for registering to seek the role of lead plaintiff is set for December 15, 2025. Investors are urged not to delay in asserting their rights to be part of this action.

Once a shareholder registers, they will gain access to monitoring software that will keep them informed about the case's progress. Crucially, registering to participate in the lawsuit is free of charge and comes without any obligations.

Why Choose the Gross Law Firm?

As a nationally recognized firm specializing in class action lawsuits, the Gross Law Firm advocates for the rights of investors affected by fraud and deceptive business practices. Their commitment lies in holding corporations accountable for irresponsible conduct, ensuring that the rights of shareholders are protected. They strive to assist investors who have encountered losses due to misleading or false information provided by companies like MoonLake Immunotherapeutics.

For further inquiries or to register for participation in this class action lawsuit, shareholders can contact the Gross Law Firm at the following details:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

By acting promptly, investors can contribute to this significant legal endeavor and seek potential recovery of their losses incurred due to alleged corporate misconduct.